Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFC3XP)

• Drug Name: TBPS Drug Info
• Synonyms: tert-butylbicyclophosphorothionate

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 104781
  CAS Number: CAS 70636-86-1
  TTD Drug ID: DMFC3XP

Molecule-Related Drug Atlas

Drug(s) Targeting GABA(A) receptor gamma-2 (GABRG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Allopregnanolone	DMNLHAC	Depression	6A70-6A7Z	approved	[17]
THIOCOLCHICOSIDE	DMEPWYA	Muscle spasm	MB47.3	Approved	[18]
ZK-93423	DMFWMKZ	Epileptic seizures	8A61-8A6Z	Phase 3	[19]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[18]
ELTANOLONE	DM38CIV	Premenstrual syndrome	GA34.40	Discontinued in Phase 3	[17]
U-78875	DM2WOPX	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 1	[20]
CGS-9896	DM39PQI	N. A.	N. A.	Terminated	[21]
CGS-17867A	DMMZJY3	Alcohol dependence	6C40.2	Terminated	[22]
AMENTOFLAVONE	DMLRNV2	Discovery agent	N.A.	Investigative	[23]
Ro-15-3505	DM4NW3U	Discovery agent	N.A.	Investigative	[24]

Drug(s) Targeting GABA(A) receptor rho3 (GABRR3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
isonipecotic acid	DMO1ZHE	Discovery agent	N.A.	Investigative	[13]
piperidine-4-sulphonic acid	DMMIZWE	Discovery agent	N.A.	Investigative	[13]
trans-3-ACPBPA	DM6HI8W	Discovery agent	N.A.	Investigative	[13]
cis-3-ACPBPA	DMQ0EA7	Discovery agent	N.A.	Investigative	[13]
5-Me-IAA	DMFZN7J	Discovery agent	N.A.	Investigative	[13]
aza-THIP	DML70NC	Discovery agent	N.A.	Investigative	[13]
TPMPA	DMBF6KS	Discovery agent	N.A.	Investigative	[13]
(+/-)-cis-2-CAMP	DMY3J0B	Discovery agent	N.A.	Investigative	[13]

Drug(s) Targeting GABA(A) receptor alpha-5 (GABRA5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flumazenil	DMPCG2L	Benzodiazepine overdose	PC91	Approved	[4]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[25]
Basmisanil	DMQ8J0U	Alzheimer disease	8A20	Phase 2	[26]
RG-7816	DMD16JK	Autism spectrum disorder	6A02	Phase 1	[27]
AMENTOFLAVONE	DMLRNV2	Discovery agent	N.A.	Investigative	[23]
Ro-15-3505	DM4NW3U	Discovery agent	N.A.	Investigative	[28]
isonipecotic acid	DMO1ZHE	Discovery agent	N.A.	Investigative	[4]
[3H]Ro154513	DMMBWKL	Discovery agent	N.A.	Investigative	[29]
[3H]CGS8216	DMLP68J	Inflammation	1A00-CA43.1	Investigative	[4]
CI-218872	DM0RH3S	Discovery agent	N.A.	Investigative	[30]

Drug(s) Targeting GABA(A) receptor delta (GABRD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Allopregnanolone	DMNLHAC	Depression	6A70-6A7Z	approved	[27]
Gaboxadol	DMI53FU	Insomnia	7A00-7A0Z	Approved	[31]
Ganaxolone	DMXJMKF	Epileptic seizures	8A61-8A6Z	Approved	[32]
SAGE-217b	DMRFK0B	Major depressive disorder	6A70.3	Phase 2	[27]
PF-4480682	DMWYJHC	Neuropathic pain	8E43.0	Discontinued in Phase 2	[33]
PF-2393296	DM5R2MG	Neuropathic pain	8E43.0	Discontinued in Phase 1	[6]
Co-60549	DMGIZHX	Anxiety disorder	6B00-6B0Z	Terminated	[34]
Org-20599	DMQU8AR	Anaesthesia	9A78.6	Terminated	[35]
RU-5135	DMCASRD	Discovery agent	N.A.	Investigative	[36]

Drug(s) Targeting GABA(A) receptor gamma-3 (GABRG3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zolpidem	DMWOSKJ	Insomnia	7A00-7A0Z	Approved	[9]
Allopregnanolone	DMNLHAC	Depression	6A70-6A7Z	approved	[26]
Clobazam - Lundbeck	DMW1OQ0	Anxiety disorder	6B00-6B0Z	Approved	[37]
Flumazenil	DMPCG2L	Benzodiazepine overdose	PC91	Approved	[9]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[38]
Thiamylal	DMHDF7B	Anaesthesia	9A78.6	Approved	[37]
Ganaxolone	DMXJMKF	Epileptic seizures	8A61-8A6Z	Approved	[26]
Mebutamate	DM0KYI4	Anxiety disorder	6B00-6B0Z	Approved	[37]
Metharbital	DM5A38V	Epilepsy	8A60-8A68	Approved	[37]
Etomidate	DMZI3WO	Anaesthesia	9A78.6	Approved	[37]

Drug(s) Targeting GABA(A) receptor alpha-2 (GABRA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flumazenil	DMPCG2L	Benzodiazepine overdose	PC91	Approved	[2]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[25]
PF-4480682	DMWYJHC	Neuropathic pain	8E43.0	Discontinued in Phase 2	[33]
CGS-17867A	DMMZJY3	Alcohol dependence	6C40.2	Terminated	[22]
AMENTOFLAVONE	DMLRNV2	Discovery agent	N.A.	Investigative	[23]
Ro-15-3505	DM4NW3U	Discovery agent	N.A.	Investigative	[28]
isonipecotic acid	DMO1ZHE	Discovery agent	N.A.	Investigative	[2]
[3H]Ro154513	DMMBWKL	Discovery agent	N.A.	Investigative	[29]
[3H]CGS8216	DMLP68J	Inflammation	1A00-CA43.1	Investigative	[2]
CI-218872	DM0RH3S	Discovery agent	N.A.	Investigative	[30]

Drug(s) Targeting GABA(A) receptor alpha-3 (GABRA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flumazenil	DMPCG2L	Benzodiazepine overdose	PC91	Approved	[3]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[25]
Adipiplon	DM821BS	Sleep-wake disorder	7A00-7B2Z	Phase 2	[39]
NS-2710	DMMUR6V	Anxiety disorder	6B00-6B0Z	Phase 2	[40]
AZD6280	DMFAZLU	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 1	[41]
AMENTOFLAVONE	DMLRNV2	Discovery agent	N.A.	Investigative	[23]
Ro-15-3505	DM4NW3U	Discovery agent	N.A.	Investigative	[28]
isonipecotic acid	DMO1ZHE	Discovery agent	N.A.	Investigative	[3]
[3H]Ro154513	DMMBWKL	Discovery agent	N.A.	Investigative	[29]
[3H]CGS8216	DMLP68J	Inflammation	1A00-CA43.1	Investigative	[3]

Drug(s) Targeting GABA(A) receptor beta-2 (GABRB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Allopregnanolone	DMNLHAC	Depression	6A70-6A7Z	approved	[17]
THIOCOLCHICOSIDE	DMEPWYA	Muscle spasm	MB47.3	Approved	[18]
Ethchlorvynol	DM53IP1	Insomnia	7A00-7A0Z	Approved	[42]
ZK-93423	DMFWMKZ	Epileptic seizures	8A61-8A6Z	Phase 3	[19]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[18]
ELTANOLONE	DM38CIV	Premenstrual syndrome	GA34.40	Discontinued in Phase 3	[17]
U-78875	DM2WOPX	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 1	[43]
CGS-9896	DM39PQI	N. A.	N. A.	Terminated	[21]
AMENTOFLAVONE	DMLRNV2	Discovery agent	N.A.	Investigative	[23]
Ro-15-3505	DM4NW3U	Discovery agent	N.A.	Investigative	[24]

Drug(s) Targeting GABA(A) receptor rho2 (GABRR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
isonipecotic acid	DMO1ZHE	Discovery agent	N.A.	Investigative	[12]
piperidine-4-sulphonic acid	DMMIZWE	Discovery agent	N.A.	Investigative	[12]
trans-3-ACPBPA	DM6HI8W	Discovery agent	N.A.	Investigative	[12]
cis-3-ACPBPA	DMQ0EA7	Discovery agent	N.A.	Investigative	[12]
5-Me-IAA	DMFZN7J	Discovery agent	N.A.	Investigative	[12]
aza-THIP	DML70NC	Discovery agent	N.A.	Investigative	[12]
TPMPA	DMBF6KS	Discovery agent	N.A.	Investigative	[12]
(+/-)-cis-2-CAMP	DMY3J0B	Discovery agent	N.A.	Investigative	[12]

Drug(s) Targeting GABA(A) receptor rho1 (GABRR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
isonipecotic acid	DMO1ZHE	Discovery agent	N.A.	Investigative	[11]
piperidine-4-sulphonic acid	DMMIZWE	Discovery agent	N.A.	Investigative	[11]
trans-3-ACPBPA	DM6HI8W	Discovery agent	N.A.	Investigative	[11]
cis-3-ACPBPA	DMQ0EA7	Discovery agent	N.A.	Investigative	[11]
5-Me-IAA	DMFZN7J	Discovery agent	N.A.	Investigative	[11]
aza-THIP	DML70NC	Discovery agent	N.A.	Investigative	[11]
TPMPA	DMBF6KS	Discovery agent	N.A.	Investigative	[11]
(+/-)-cis-2-CAMP	DMY3J0B	Discovery agent	N.A.	Investigative	[11]
CACA	DMPKFYZ	Discovery agent	N.A.	Investigative	[44]

Drug(s) Affected By Gamma-aminobutyric acid receptor subunit gamma-2 (GABRG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[45]
Flunitrazepam	DMGR5Z3	Insomnia	7A00-7A0Z	Approved	[46]
Flumazenil	DMPCG2L	Benzodiazepine overdose	PC91	Approved	[47]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[48]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[49]
Methamphetamine	DMPM4SK	Anxiety		Approved	[50]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[51]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[52]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[53]
Manganese	DMKT129	N. A.	N. A.	Investigative	[54]

Drug(s) Affected By Gamma-aminobutyric acid receptor subunit beta-2 (GABRB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[56]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[45]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[57]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[56]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[58]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[59]
Naltrexone	DMUL45H	Alcohol dependence	6C40.2	Approved	[60]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[61]
CHLORIDE	DM1TJXA	Solid tumour/cancer	2A00-2F9Z	Phase 3	[62]

Drug(s) Affected By Gamma-aminobutyric acid receptor subunit alpha-1 (GABRA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[63]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[64]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[65]
Flunitrazepam	DMGR5Z3	Insomnia	7A00-7A0Z	Approved	[46]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[66]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[67]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[68]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[52]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[53]
Muscimol	DMNTF2O	Discovery agent	N.A.	Investigative	[46]

Drug(s) Affected By Gamma-aminobutyric acid receptor subunit beta-3 (GABRB3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[56]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[69]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[70]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[71]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[65]
Flunitrazepam	DMGR5Z3	Insomnia	7A00-7A0Z	Approved	[46]
Vitamin A	DMJ2AH4	Night blindness	9D45	Approved	[72]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[73]
Flumazenil	DMPCG2L	Benzodiazepine overdose	PC91	Approved	[47]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
GABA(A) receptor alpha-2 (GABRA2)	TTBMV1G	GBRA2_HUMAN	Blocker (channel blocker)	[2]
GABA(A) receptor alpha-3 (GABRA3)	TT37EDJ	GBRA3_HUMAN	Blocker (channel blocker)	[3]
GABA(A) receptor alpha-5 (GABRA5)	TTNZPQ1	GBRA5_HUMAN	Blocker (channel blocker)	[4]
GABA(A) receptor beta-2 (GABRB2)	TTZA1NY	GBRB2_HUMAN	Blocker (channel blocker)	[5]
GABA(A) receptor delta (GABRD)	TTGXH6N	GBRD_HUMAN	Blocker (channel blocker)	[6]
GABA(A) receptor epsilon (GABRE)	TTBY4OD	GBRE_HUMAN	Blocker (channel blocker)	[7]
GABA(A) receptor gamma-2 (GABRG2)	TT06RH5	GBRG2_HUMAN	Blocker (channel blocker)	[8]
GABA(A) receptor gamma-3 (GABRG3)	TTEX6LM	GBRG3_HUMAN	Blocker (channel blocker)	[9]
GABA(A) receptor pi (GABRP)	TT3E0DI	GBRP_HUMAN	Blocker (channel blocker)	[10]
GABA(A) receptor rho1 (GABRR1)	TT6XFEU	GBRR1_HUMAN	Blocker (channel blocker)	[11]
GABA(A) receptor rho2 (GABRR2)	TTQMXLS	GBRR2_HUMAN	Blocker (channel blocker)	[12]
GABA(A) receptor rho3 (GABRR3)	TT4N6D8	GBRR3_HUMAN	Blocker (channel blocker)	[13]
GABA(A) receptor theta (GABRQ)	TTXDUR9	GBRT_HUMAN	Blocker (channel blocker)	[14]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Gamma-aminobutyric acid receptor subunit alpha-1 (GABRA1)	OTC2W96H	GBRA1_HUMAN	Protein Interaction/Cellular Processes	[15]
Gamma-aminobutyric acid receptor subunit beta-2 (GABRB2)	OTAOZIGX	GBRB2_HUMAN	Protein Interaction/Cellular Processes	[15]
Gamma-aminobutyric acid receptor subunit beta-3 (GABRB3)	OT80C3D4	GBRB3_HUMAN	Protein Interaction/Cellular Processes	[16]
Gamma-aminobutyric acid receptor subunit gamma-2 (GABRG2)	OTGNDWUO	GBRG2_HUMAN	Protein Interaction/Cellular Processes	[15]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4320).
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405).
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406).
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408).
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 411).
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 416).
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 417).
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 414).
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 419).
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 420).
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 421).
• [13] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 422).
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 418).
• [15] [3H]Ethynylbicycloorthobenzoate ([3H]EBOB) binding in recombinant GABAA receptors. Neurotoxicology. 2003 Dec;24(6):817-24. doi: 10.1016/S0161-813X(03)00051-2.
• [16] The interactions of hexachlorocyclohexane isomers with human gamma-aminobutyric acid(A) receptors expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1997 Sep;282(3):1557-64.
• [17] Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9.
• [18] 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
• [19] Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carbolin... J Med Chem. 1990 Mar;33(3):1062-9.
• [20] 3-Phenyl-substituted imidazo[1,5-alpha]quinoxalin-4-ones and imidazo[1,5-alpha]quinoxaline ureas that have high affinity at the GABAA/benzodiazepin... J Med Chem. 1996 Sep 13;39(19):3820-36.
• [21] Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66.
• [22] 2,5-Dihydropyrazolo[4,3-c]pyridin-3-ones: functionally selective benzodiazepine binding site ligands on the GABAA receptor. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3441-4.
• [23] Semisynthetic preparation of amentoflavone: A negative modulator at GABA(A) receptors. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2281-4.
• [24] Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6.
• [25] New anticonvulsants: Schiff bases of gamma-aminobutyric acid and gamma-aminobutyramide. J Med Chem. 1980 Jun;23(6):702-4.
• [26] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [27] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [28] The GABA(A) receptor as a target for photochromic molecules. Bioorg Med Chem. 2010 Nov 15;18(22):7731-8.
• [29] Synthesis and pharmacological properties of novel 8-substituted imidazobenzodiazepines: high-affinity, selective probes for alpha 5-containing GABA... J Med Chem. 1996 Apr 26;39(9):1928-34.
• [30] Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
• [31] Gaboxadol--a new awakening in sleep.Curr Opin Pharmacol.2006 Feb;6(1):30-6.
• [32] Ganaxolone, a selective, high-affinity steroid modulator of the gamma-aminobutyric acid-A receptor, exacerbates seizures in animal models of absence. Ann Neurol. 1998 Oct;44(4):688-91.
• [33] WO patent application no. 2014,1515,17, Methods of improving microvascular integrity.
• [34] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007012)
• [35] The anaesthetic action and modulation of GABAA receptor activity by the novel water-soluble aminosteroid Org 20599. Neuropharmacology. 1996;35(9-10):1209-22.
• [36] Complex interactions between the steroid derivative RU 5135 and the GABAA-receptor complex. Eur J Pharmacol. 1992 Oct 1;227(2):147-51.
• [37] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [38] Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels. Epilepsia. 2006 Apr;47(4):704-16.
• [39] Discriminative stimulus properties of GABAA receptor positive allosteric modulators TPA023, ocinaplon and NG2-73 in rats trained to discriminate chlordiazepoxide or zolpidem. Eur J Pharmacol. 2011 Oct 1;668(1-2):190-3.
• [40] GABAA receptor subtype-selective modulators. I. alpha2/alpha3-selective agonists as non-sedating anxiolytics. Curr Top Med Chem. 2011;11(9):1176-202.
• [41] AZD6280, a novel partial -aminobutyric acid A receptor modulator, demonstrates a pharmacodynamically selective effect profile in healthy male volunteers.J Clin Psychopharmacol.2015 Feb;35(1):22-33.
• [42] DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
• [43] High-affinity alpha-aminobutyric acid A/benzodiazepine ligands: synthesis and structure-activity relationship studies of a new series of tetracycli... J Med Chem. 1996 Nov 8;39(23):4654-66.
• [44] Characterization of bicuculline/baclofen-insensitive (rho-like) gamma-aminobutyric acid receptors expressed in Xenopus oocytes. II. Pharmacology of gamma-aminobutyric acidA and gamma-aminobutyric acidB receptor agonists and antagonists. Mol Pharmacol. 1993 Apr;43(4):609-25.
• [45] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [46] p-(4-Azipentyl)propofol: a potent photoreactive general anesthetic derivative of propofol. J Med Chem. 2011 Dec 8;54(23):8124-35. doi: 10.1021/jm200943f. Epub 2011 Nov 10.
• [47] Cloning of cDNAs encoding the human gamma-aminobutyric acid type A receptor alpha 6 subunit and characterization of the pharmacology of alpha 6-containing receptors. Mol Pharmacol. 1996 Feb;49(2):253-9.
• [48] Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer. Mol Oncol. 2011 Oct;5(5):438-53. doi: 10.1016/j.molonc.2011.07.003. Epub 2011 Jul 26.
• [49] Heterogeneity of GABA(A) receptor-mediated responses in the human IMR-32 neuroblastoma cell line. J Neurosci Res. 2000 May 15;60(4):504-10. doi: 10.1002/(SICI)1097-4547(20000515)60:4<504::AID-JNR9>3.0.CO;2-Y.
• [50] Haplotype association between GABAA receptor gamma2 subunit gene (GABRG2) and methamphetamine use disorder. Pharmacogenomics J. 2005;5(2):89-95. doi: 10.1038/sj.tpj.6500292.
• [51] Benzo[a]pyrene-induced changes in microRNA-mRNA networks. Chem Res Toxicol. 2012 Apr 16;25(4):838-49.
• [52] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [53] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [54] Gene expression profiling of human primary astrocytes exposed to manganese chloride indicates selective effects on several functions of the cells. Neurotoxicology. 2007 May;28(3):478-89.
• [55] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [56] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [57] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [58] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [59] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [60] Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol. 2009 Jul;14(3):328-37.
• [61] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [62] A novel allosteric modulatory site on the GABAA receptor beta subunit. Neuron. 1994 Apr;12(4):775-82. doi: 10.1016/0896-6273(94)90330-1.
• [63] GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology (Berl). 2005 Jul;180(2):191-205. doi: 10.1007/s00213-005-2212-8. Epub 2005 Apr 28.
• [64] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [65] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [66] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [67] Genetic essential tremor in gamma-aminobutyric acidA receptor alpha1 subunit knockout mice. J Clin Invest. 2005 Mar;115(3):774-9. doi: 10.1172/JCI23625.
• [68] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [69] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [70] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [71] GABA receptor subunit composition relative to insecticide potency and selectivity. Toxicol Lett. 2001 Jul 6;122(3):215-22. doi: 10.1016/s0378-4274(01)00366-6.
• [72] Retinoic acid, GABA-ergic, and TGF-beta signaling systems are involved in human cleft palate fibroblast phenotype. Mol Med. 2006 Sep-Oct;12(9-10):237-45. doi: 10.2119/2006C00026.Baroni.
• [73] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.